Alvotech Reports Initiation of Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria
Shots:
- The company initiates the PK study evaluating the PK, safety, and tolerability of AVT05 vs Simponi in healthy adult patients
- A biosimilar to Humira, Alvotech's first commercially available product has been approved in 35 countries globally and has been launched in the EU & Canada. Golimumab is a mAb that inhibits TNF alpha
- The eight products and product candidates in Alvotech's current portfolio are intended to treat cancer, osteoporosis, respiratory illnesses, and autoimmune diseases. AVT05, a biosimilar candidate for Simponi and Simponi Aria has not received regulatory approval in any country
Ref: Globenewswire | Image: Alvotech
Related News:- Alvotech and Cipla Receive Marketing Authorization for AVT02 (biosimilar, adalimumab) in Australia
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
